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Abstract
OBJECTIVE—Chronic pelvic pain (CPP) affects 15% of women and has a high rate of 
psychiatric comorbidity. Vulvodynia, a vulvar pain syndrome that includes vulvar vestibulitis, is 
the most common subtype of CPP. This study examined the efficacy of lamotrigine for the 
treatment of CPP using an open-label design.
STUDY-DESIGN—Forty-three women with CPP were recruited from a specialty pelvic pain 
clinic. Of these, 31 completed 8 weeks of active treatment. Outcome variables included the McGill 
Pain Rating Index and subscales of pain intensity and the Hamilton Depression and Anxiety 
Rating Scales.
RESULTS—We found significant reductions in all pain and mood measures at the 8-week visit 
compared to baseline. In particular, women with vulvodynia-type CPP (N=17) had robust 
reductions in pain and mood symptoms.
CONCLUSION—CPP is a heterogeneous disorder, with psychiatric comorbidity and poor 
treatment response. This open-label study suggests that treatment with lamotrigine in women with 
the vulvodynia subtype of CPP may be helpful in addressing both the pain and mood symptoms 
associated with this disorder.
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We found a clinically significant response to treatment with lamotrigine as 
evidenced by decreased pain scores … and improved mood and anxiety symptoms.
Chronic pelvic pain (CPP) has been estimated to affect 15% of the adult female population 
and account for 1 in 7 primary health care visits and 40% of diagnostic laparoscopies 
performed in general hospitals.1,2 CPP has been defined as noncyclic pelvic pain of >6 
months duration that is not relieved by opioid medications.1 CPP is a heterogeneous disorder 
with multiple and often unknown causes and poor treatment response.3,4 Symptoms of CPP 
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can include dysmenorrhea, dyspareunia and other nonspecific complaints of lower 
abdominal and vulvar pain.5–7 Previous studies have demonstrated high rates of psychiatric 
disorders in patients with various types of chronic pain,8 and CPP, in particular, has been 
associated with a high prevalence of depression and posttraumatic stress disorder (PTSD).9
Although multiple studies have shown an association between abuse and psychologic 
distress with pelvic pain, it remains unclear whether all types of CPP disorder are equally 
affected. Two studies demonstrate that women with vulvodynia (pain localized to the vulva) 
are less likely to have psychologic disturbance, sexual and/or physical abuse history, severe 
pain and other somatic complaints compared with women with other types of CPP.10,11 
Alternatively, women with diffuse pain conditions report more depression, anxiety and 
severity of pain than women with more focused pain,12 and those with intermittent pain 
(cyclical, i.e., with dysmenorrhea) have less psychologic distress and fewer histories of 
abuse than those with continuous chronic pain.13 Leserman et al14 recently formulated 7 
diagnostic subtypes of CPP and noted that patients with diffuse abdominal or pelvic pain 
had more trauma and worse mental and physical health status compared with patients with 
vulvovaginal pain and cyclic pain.
The vulvar pain syndromes vulvodynia and vulvar vestibulitis, which have recently been 
reclassified by the International Society for the Study of Vulvovaginal Disease under the 
common diagnosis of vulvodynia, are the most common type of CPP.15 Although the cause 
of vulvodynia remains unclear, current theories state that it may be a disorder of the central 
nervous system (CNS) pain regulatory pathways.15,16 Multiple treatment options are 
available for vulvodynia with varying degrees of efficacy, but one of the most common is 
tricyclic antidepressants (TCAs).15,1 TCAs, however, have significant side effects and 
demonstrate inconsistent efficacy in pelvic pain.18 Therefore, because many women with 
CPP are often refractory to treatment and have significant psychiatric comorbidity, we were 
interested in studying the efficacy of a CNS agent, lamotrigine, which is an anticonvulsant 
with demonstrated efficacy in both mood and pain symptoms.
Lamotrigine (Lamictal, GlaxoSmithKline Pharmaceuticals, Durham, North Carolina), 3,5-
diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine, is an anticonvulsant and mood-stabilizing 
medication that acts by stabilizing the slow inactivated conformation of type IIA neuronal 
sodium channels, resulting in inhibition of repetitive firing of action potentials under 
conditions of sustained neuronal depolarization.19 Lamotrigine is thought to suppress the 
excessive release of excitatory amino adds (principally glutamate). Glutamate, a candidate 
neurotransmitter in spinal cord nociceptive pathways, has been implicated in the 
mechanisms that may be involved in chronic pain, such as central sensitization and wind-up, 
both of which can be inhibited by NMDA (N-methyl-D-aspartic acid) receptor antagonists.20 
By inhibiting the pathologic release of glutamate, lamotrigine has the potential to be 
antinociceptive and prevent the mechanisms responsible for the establishment of chronic 
pain. Lamotrigine has FDA approval for treatment of bipolar major depression and more 
recently lamotrigine has also been demonstrated to be useful for the treatment of chronic 
pain syndromes. It has been shown to be efficacious in treating neuropathic pain in patients 
with diabetes and human immune deficiency (HTV) infection, including recent randomized 
controlled trials (Level I),21–25 and migraine pain.26 However, to date no studies have 
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examined the efficacy of lamotrigine for CPP, a pain condition that continues to be a major 
therapeutic challenge.
In this study, we performed an open-label trial to determine how lamotrigine would affect 
degree of pelvic pain, number of somatic complaints, psychologic distress (depression and 
anxiety) and quality of life in women with CPP, with a particular focus on vulvodynia-type 
pain. We also included patients with other subtypes of pelvic pain, including generalized 
diffuse abdominal pain and neuropathic pain.
Materials and Methods
Sample
In this open-label trial of lamotrigine, we screened and enrolled 43 women with CPP, with a 
particular focus on vulvodynia, from the University of North Carolina Pelvic Pain Clinic 
from November 2004 to December 2006. Of these, 31 (72%) completed the full 8 weeks of 
the active treatment phase and were considered study completers. Twelve women dropped 
out before week 8, and 9 of these 12 dropped out very early in the study as a result of 
concerns unrelated to the study medication; 7 decided not to participate in the study because 
of inconvenience (e.g., travel distance, frequency of study visits or concerns about 
participating in research), and 2 developed unrelated and unexpected health problems. The 
remaining 3 of 12 subjects developed medication side effects (minor rash, headache and 
fatigue) that resulted in leaving the study. The 31 completers did not differ from the 12 who 
dropped out on education or because of type of CPP diagnosis, however, those who dropped 
out tended to be on average 8 years younger (p=0.05). Of the 31 completers, 10 discontinued 
the study during the maintenance phase of treatment (between weeks 8 and 12). Most of 
those who dropped out in the maintenance period experienced medication side effects, 
including fatigue, nausea, headaches and rash. Thus 21 patients completed the entire study 
(through, the maintenance 12-week period). Overall, 13 subjects (30%) dropped out of the 
study because of medication side effects.
Patients were eligible if they met the following inclusion criteria: (1) CPP of at least 6 
months duration diagnosed by a gynecologist in the outpatient Pelvic Pain Clinic at the 
University of North Carolina at Chapel Hill; (2) average pain of at least 4 on a visual analog 
pain scale filled out each day for 1 week; (3) age 18–60 years; and (4) having 1 of 3 types of 
CPP as diagnosed by a gynecologist who specializes in chronic pelvic pain. The 3 types of 
CPP included (1) diffuse abdominal pain (e.g., pain elicited during examination that was not 
localized and was without a single reproducible point or tender palpable spot)14; (2) 
neuropathic type pain (e.g., a mix of pain disorders initiated after surgery); and (3) 
vulvodynia pain (including vulvar vestibulitis). This categorization of pelvic pain has been 
previously shown to discriminate between types of CPP on mental and physical health.14
We recruited 2:1 vulvodynia-type CPP vs. the other subtypes based on our clinical 
experience with the CPP population and our previous work demonstrating that women with 
the vulvodynia subtype of CPP are less likely to have significant psychologic disturbance, 
sexual and/or physical abuse history, severe pain and other somatic complaints compared 
with women with other types of CPP. Additionally, we hypothesized that complex 
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abdominal pain likely has multiple causative contributions that unidimentional therapy 
would not address. Exclusion criteria included (1) active systemic diseases or disorders that 
would interfere with participation (e.g., heart, lung, kidney, liver, diabetes, cancer, stroke, 
seizures, psychotic disorders, malnutrition, surgery in previous 6 months, pregnancy, 
deafness, and blindness);, (2) current alcohol or substance dependence (e.g., marijuana, 
PCP, cocaine, heroin, LSD); (3) any use of valproic acid (Depakote) within 4 weeks of the 
study because of potential drug interaction with lamotrigine; (4) initialing use of 
antidepressant medications during the 1 month before the study; and (5) < 8 years of 
education, illiterate, and/or non-English speaking. Participants were allowed to continue 
taking analgesics (including TCAs, opioids and nonsteroidal antiinflammatory drugs) if they 
had been receiving them for at least 4 weeks before the study. Similarly, herbal remedies 
and alternative therapies such as massage and acupuncture were permitted to be continued if 
patients had been receiving them before study participation. Initiation of a new analgesic for 
use during the study was not permitted.
Study Design
This 14-week study design included (1) Screening and Baseline Visit; (2) an 8-week Dose 
Escalation Phase; (3) a 3-week Dose Maintenance Phase; and (4) a 2-week Dose Tapering 
Phase. In total, there were 8 patient contact visits, including 5 office visits and 3 phone visits 
for each study participant. Questionnaire evaluation was performed at baseline and at the 
end of weeks 8 and 12.
Screening and Baseline Visit—Study participants were patients in the Pelvic Pain 
Clinic. This research protocol was approved by the University of North Carolina at Chapel 
Hill Institutional Review Board. All patients gave informed consent based on standard 
procedures by the Committee for the Protection of Human Subjects. Patients completed a 
pain diary card filled out during the week before the screening and baseline visit. Risks, 
benefits and side effects of administration of lamotrigine were discussed with all potential 
study participants, including the small risk for serious rash (Stevens-Johnson syndrome or 
toxic epidermal necrolysis), that have been reported secondary to exposure to lamotrigine. 
Patients who met all inclusion/exclusion criteria completed baseline questionnaires and 
interviews and were enrolled into the open-label study.
Drug Dose Escalation Phase—Treatment was initiated at a daily dose of 25 mg for 2 
weeks, increased to 50 mg/day for 2 weeks, and subsequently to 100, 200, 300 and 400 mg/
day, each dose for an additional week. The dosing schedule was once daily during the first 2 
weeks and twice daily for the remaining 6 weeks.
Drug Maintenance Phase—The target maintenance dose was 400 mg/day (200 mg twice 
per day), although the minimum efficacious dose was 200 mg, if side effects did not permit 
further dose escalation.
Dose Tapering Phase—During the 2-week taper phase, study participants had the dose 
of lamotrigine reduced by 50% every 5 days until they were safely discontinued from the 
medication.
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We chose 5 primary outcome variables, as follows: (1) the McGill Pain Rating Index, 
consisting of 15 pain descriptors ranging from 0 (none) to 3 (severe) describing pain for the 
previous month27; (2) the McGill Visual Analog Scale (VAS) of overall pain intensity for 
the past month, ranging from 0 (no pain) to 10 (worst possible pain); (3) the McGill Pain 
Intensity Scale modified to rate pelvic pain from 0 (no pain) to 5 (excruciating); (4) the 
Hamilton Depression Rating Scale (HAM-D), a standard interview-based measure of 
depression28; and (5) the Hamilton Anxiety Rating Scale (HAM-A), a standard interview-
based measure of anxiety.29
Statistical Analysis
All statistical calculations were done using SAS version 8.2 (SAS Institute Inc., Cary, North 
Carolina). The main demographic and baseline characteristics are reported as means and 
SDs for continuous variables and as percentages for categorical variables. All outcome 
variables were approximately normally distributed. We compared all patients with CPP 
before and after receiving lamotrigine using a paired t test on the primary outcome variables. 
Comparisons were made from baseline to 8 weeks and from baseline to 12 weeks. We also 
examined changes within each type of CPP (e.g., diffuse abdominal, neuropathic, 
vulvodynia) using a paired t test from baseline to 8 and 12 weeks. We also used the general 
linear model with t test comparisons between the 3 subgroups of CPP patients to compare 
these groups on antidepressant use. Unpaired t tests were also used to compare study 
completers to noncompleters.
The primary aim of this study was to determine whether lamotrigine appears to have 
efficacy for patients with CPP, with a particular focus on vulvodynia, in terms of 
improvements in physical and psychological health.
Power Analysis—Our statistical power analysis was based on a paired t test assuming a 
standard difference (d) between paired outcomes over time of 0.60 (moderate effect size30), 
an SD of 1 for each outcome variable and a correlation of 0.50 between variables over time. 
We considered this difference to be a clinically meaningful change in symptoms and pain. 
With N = 31 (8-week analysis) and effect size d = 0.60, our power to detect this moderate 
difference was 0.90, assuming a 2-tailed test and alpha set at 0.05. With N=21 (12-week 
analysis) and effect size d = 0.60, our power was 0.74 using the same assumptions. Analyses 
within subtypes of CPP were limited to testing only large effects (d=0.70–0.80), yielding 
acceptable power (0.77–0.87) only for the vulvodynia pain group. The N of the other 2 
groups required very large effect sizes (1.2) to have marginal power (> 0.75).
Results
Table I describes the demographic information of our sample. The average age of the 31 
patients completing 8 weeks of lamotrigine was 41 years (SD 12.6, range 23–67) and 
average educational level was 15.3 years (SD 1.8). All but 1 subject was Caucasian. The 
average dose of lamotrigine was 340 mg in those completing 8 weeks of treatment and 367 
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mg in those completing the 12-week maintenance phase. Types of CPP included vulvodynia 
pain (17), diffuse abdominal pain (7) and neuropathic pain (7).
The 10 participants who dropped out of the study after 8 weeks were not different in age, 
diagnosis, baseline depression or baseline pain compared with the 21 participants who 
completed 12 weeks of treatment. However, the dropouts tended to have on average 2 years 
less education (p = 0.0009). At the time of study entry, most patients were using 
concomitant medications, (ranging from 1 to 5 medications) such as antiinflammatories, 
antidepressants, narcotic pain medications and benzodiazepines. Approximately half 
(48.4%) of the patients were on antidepressant medication at baseline. Antidepressant use 
did not vary across type of CPP diagnosis (χ2 = 1.92, p = 0.38, N = 31). The baseline mean 
HAM-D score in the group as a whole was 12.3, which is consistent with a mild depressive 
disorder.31
When examining the group as a whole, we found that patients reported significant 
reductions on the McGill Pain Rating Index, McGill Visual Analog Scale and overall pain 
intensity, pelvic pain intensity, Hamilton Depression and Hamilton Anxiety Scales at the 8- 
and 12-week visits compared to baseline (Tables II and III, respectively). As described in 
Table II, at 8 weeks of treatment with lamotrigine in the whole group, we found a robust 
treatment response with clinically and statistically significant reductions in pain (McGill 
Pain Rating Index, p=0.003; McGill pain intensity (VAS), p < 0.0001; pelvic pain intensity, 
p < 0.0001), improvement in mood (Hamilton Depression, p = 0.002) and anxiety symptoms 
(Hamilton Anxiety, p = 0.02). At 12 weeks of treatment (Table III), we saw a continued 
treatment response with further improvements in mood and anxiety symptoms (Hamilton 
Depression, p = 0.001; Hamilton Anxiety, p = 0.004).
When we further analyzed the data by the 3 subtypes of pelvic pain (Tables IV and V), we 
noticed a marked difference in response to treatment. The subjects in the vulvodynia pain 
group had robust reductions on all measures of pain at both the 8- and 12-week visits 
compared to baseline (Table IV and V, respectively). At the 8-week assessment, analyses of 
pain rating scales in the vulvodynia pain group were as follows: McGill Pain Rating Index, p 
= 0.002; McGill VAS overall pain intensity, p = 0.0001, and pelvic pain intensity, p < 
0.0001. At the 12-week assessment, analyses of pain rating scales in the vulvodynia pain 
group were as follows: McGill Pain Rating Index, p=0.015; McGill VAS overall pain 
intensity, p = 0.0003; and McGill VAS pelvic pain intensity, p = 0.002. Analysis of mood 
and anxiety symptoms demonstrated nonsignificant reductions in depression and anxiety at 8 
weeks (HAM-D, p=0.113; HAM-A, p = 0.061), with significant reductions in depression 
and anxiety symptoms at the 12-week visit (HAM-D, p = 0.003; HAM-A, p=0.001). These 
data are consistent with the slower onset of the mood-stabilizing effects of lamotrigine 
described in the literature.32 In contrast, subjects with the diffuse abdominal pain subtype of 
CPP showed minimal response to lamotrigine on all measures. Those with the neuropathic 
pain subtype of CPP showed no significant changes on any measure; however, there were 
nonsignificant reductions in depression and anxiety equivalent to a > 1 SD change.
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CPP is a heterogeneous disorder, with often poor treatment response and significant 
psychiatric co-morbidity. Our open-label pilot study suggests that the use of lamotrigine in 
the treatment of patients with CPP may be helpful in addressing both the pain and mood 
symptoms associated with this disorder. We found a clinically significant response to 
treatment with lamotrigine as evidenced by decreased pain scores (McGill Pain Rating 
Index, VAS pain intensity and pelvic pain) and improved mood and anxiety symptoms. In 
addition, we found that patients with the CPP subtype of vulvodynia demonstrated a 
particularly robust response that was clinically and statistically significant to treatment with 
lamotrigine in terms of both pain and mood symptoms. This is in contrast to patients with 
other types of pelvic pain (diffuse abdominal and neuropathic) who did not have a clinically 
significant reduction in pain. Of interest, despite the small number, patients with the 
neuropathic subtype of CPP had large drops in depression and anxiety (> 1 SD), albeit 
nonsignificant. With larger samples, these changes would likely have readied statistical 
significance.
Current theories suggest that CPP is a biopsychosocial disorder in which psychologic events 
such as sexual abuse and trauma may interact with structural and physiologic factors to 
produce symptoms.9,16 These interactions determine how patients cope with their symptoms 
and how they respond to treatments, including psychologic as well as medical and surgical 
treatments. As described earlier, recent work has demonstrated that women with vulvodynia 
have better mental health and decreased rates of sexual and/or physical abuse history 
compared with women with other subtypes of pelvic pain.10,11,14 Thus we hypothesize that a 
potential explanation for the robust response to treatment with lamotrigine seen in CPP 
patients with the subtype of vulvodynia may be due to differences in CNS pain regulatory 
mechanisms in this type of CPP vs. other subtypes. Patients with vulvodynia tend to have a 
more circumscribed type of pain, especially compared to those with diffuse abdominal pain. 
More diffuse-type pain may indicate greater dysregulation in central pain regulatory 
pathways33,34 and thus may be less likely to respond to a unidimensional treatment 
modality.
Limitations of this pilot study included its open-label design with a lack of control group and 
a small sample size, particularly in the subtype analysis of CPP. Also, we had a dropout rate 
of 28%; however, most of these patients left for reasons unrelated to the medication. In 
addition, because our results are based on a single cohort from a referral-based pelvic pain 
clinic, we may have introduced a sample bias and limited the generalizability of our findings 
to a more diverse CPP population. The clinic tends to see patients who are treatment 
refractory. Responses of a less refractory patient group might be better than those in the 
current study. Despite these limitations, we have found highly favorable results from this 
pilot study that may provide the basis for a placebo-controlled clinical trial of lamotrigine 
with a larger sample of CPP patients.
In conclusion, the results of this pilot trial provide proof of concept for the use of 
psychotropic medications, in particular anticonvulsant medications with mood-stabilizing 
properties, such as lamotrigine, in the treatment of pelvic pain. Furthermore, treatment of 
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CPP needs to be specifically tailored based on the subtype of CPP (i.e., vulvodynia) because 
this may greatly influence the efficacy of a particular intervention.
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Table I








Age (yr) 41.0 39.90
Education (yr) 15.3 15.95
Race (% white) 95% 100%
Average dose of lamotrigine (mg) 340 367
Diagnostic subtype of CPP by group
  Vulvodynia 17 13
  Diffuse abdominal 7 4
  Neuropathic pain 7 4
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